You are viewing the site in preview mode
Skip to main content
|
Variables
|
β-lactam group (n = 72)
|
Combination group (n = 93)
|
P-value
|
|---|
|
Demographic data
|
|
Age, years
|
61 ± 11
|
62 ± 10
|
0.296
|
|
Male sex
|
59 (81.9%)
|
59 (63.4%)
|
0.009
|
|
Smoking history
|
29 (40.3%)
|
27 (29.0%)
|
0.130
|
|
Comorbid conditions
|
|
Hypertension
|
14 (19.4%)
|
28 (30.1%)
|
0.119
|
|
Diabetes mellitus
|
5 (6.9%)
|
12 (12.9%)
|
0.212
|
|
Cardiovascular diseases
|
5 (6.9%)
|
2 (2.2%)
|
0.130
|
|
Chronic lung diseases
|
3 (4.2%)
|
6 (6.5%)
|
0.733
|
|
Chronic liver diseases
|
3 (4.2%)
|
3 (3.2%)
|
1.000
|
|
Chronic renal diseases
|
0 (0.0%)
|
6 (6.5%)
|
0.036
|
|
Types of β-lactams
|
|
Cefepime
|
40 (55.6%)
|
64 (68.8%)
|
0.080
|
|
Ceftazidimea
|
20 (27.8%)
|
2 (2.2%)
|
< 0.001
|
|
Piperacillin/tazobactam
|
6 (8.3%)
|
21 (22.6%)
|
0.014
|
|
Carbapenem
|
6 (8.3%)
|
6 (6.5%)
|
0.644
|
|
Duration of antibiotic administration, days
|
12.4 (8.9–16.2)
|
11.7 (9.1–14.4)
|
0.646
|
|
Severity variables
|
|
Presence of bacteremia
|
16 (22.0%)
|
12 (12.9%)
|
0.114
|
|
Duration of neutropenia, days
|
1.5 (0.9–3.1)
|
1.4 (1.0–2.9)
|
0.773
|
|
CRP, mg/dL
|
15.9 (6.5–24.0)
|
17.0 (6.4–25.9)
|
0.669
|
|
CURB-65
|
1 (0–2)
|
1 (0–2)
|
0.898
|
|
MASCC risk index
|
16 (13–18)
|
16 (16–21)
|
0.059
|
- Data are expressed as number (%) of patients, mean ± SD, or median (IQR)
- aCeftazidime was administered with tobramycin for an initial 3–5 days
- Abbreviations: CRP C-reactive protein, MASCC Multinational Association for Supportive Care in Cancer, SD Standard deviation, IQR interquartile range
